Its clear as day to me. Atomo had sold 1.2M devices over the past 3 years. Atomos last 3 orders from NG Biotech now total 1.39M devices through to 31st July 2020. Atomos 3 orders from NG Biotech are already greater than the total number of devices ever sold.
This is only the beginning for Atomo. I have found countless articles that say TODAY, NG Biotech can produce hundreds of thousands of tests. But their plan is to produce 1-2M tests per month from July onwards. This is in-line with Atomos additional capacity that will come online in July.
NG Biotech is the ONLY approved company to market its rapid diagnostic serological test "NG-Test IgG-IgM Covid 19" in France. This is clinically validated in France and has European approval. The first customer was the French Army, and now a 15k person trial (13k health workers and 2k patients) is underway over 10 hospitals and health centers over the ille-et-vilaine region. NG Biotech is making serious progress in France and Atomo will be apart of this.
Only just last week, NG Biotech entered into an agreement with Eurobio Scientific for the distribution in France of the rapid diagnostic test kits to healthcare professionals and nursing homes. This is great and it will be a key step for NG Biotech to get this going across the country.
Its really up to you in how you view the company. You can go by share price movement or you can go by fundamentals. I personally go by fundamentals and have much more to confirm my confidence. Plus here is something so simple for anyone to understand. Atomo earned $883,302 revenue from sale of goods (notes in balance sheet) in Half yearly FY2020. If Atomo has already got 1.39M in orders from NG Biotech, will the revenue from these orders be greater or not greater?? I know the answer and it looks like Revenue GROWTH to me. Just need to be PATIENT
